2026-02-24
Alcohol, Aging, and Long-Term Health: What the Evidence Shows
Alcohol consumption interacts with aging biology in complex ways. This article covers the liver, brain, cardiovascular, and cancer evidence, plus what nutritional strategies can mitigate harm.
2026-02-24
Longevity Biomarkers: What to Test, What the Results Mean, and How to Track Progress
Biological age testing spans conventional labs (HbA1c, CRP, lipids) to newer epigenetic clocks and proteomic aging scores. Most conventional biomarkers are actionable today; epigenetic clocks measure biological vs. chronological age but their clinical utility for intervention-guiding remains limited. A pragmatic panel of validated tests provides meaningful signal about longevity trajectory.
2026-02-20
Berberine for Fatty Liver Risk (MASLD): Human Trial and Meta-Analysis Update
Evidence from randomized studies suggests berberine can improve liver fat-related markers in selected metabolic-risk groups, but protocol quality and baseline risk drive response.
2026-02-20
Liver Enzyme Elevation Risk: Silymarin, NAC, and Berberine With Lifestyle First
Elevated liver enzymes improve most with weight, glucose, and alcohol correction. Silymarin, NAC, and berberine can be adjuncts in selected metabolic-risk contexts.
2026-02-19
Berberine for Metabolic Health: Evidence from Human Trials
Berberine activates AMPK through mild mitochondrial Complex I inhibition, producing improvements in glucose metabolism and modest weight loss in meta-analyses of clinical trials.